½ÃÀ庸°í¼­
»óǰÄÚµå
1150064

¼¼°èÀÇ ¿°Áõ¼º ÀåÁúȯ Ä¡·á ½ÃÀå : Á¡À¯À², ±Ô¸ð, µ¿Çâ, ¾÷°è ºÐ¼® - ÀûÀÀÁõº°, ¾àÁ¦ Ŭ·¡½ºº°, Åõ¿© °æ·Îº°, À¯Åë ä³Îº°, Áö¿ªº°, ºÎ¹® ¿¹Ãø(2022-2030³â)

Inflammatory Bowel Disease Treatment Market Share, Size, Trends, Industry Analysis Report, By Disease indication; By Drug Class Insights; By Route of Administration; By Distribution Channel; By Region; Segment Forecast, 2022 - 2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Polaris Market Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 114 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°èÀÇ ¿°Áõ¼º ÀåÁúȯ Ä¡·á ½ÃÀå ±Ô¸ð´Â 2030³â±îÁö 308¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ ¿°Áõ¼º ÀåÁúȯ Ä¡·á(Inflammatory Bowel Disease Treatment) ½ÃÀå¿¡ ´ëÇØ Á¶»çÇßÀ¸¸ç, ½ÃÀå ¿ªÇÐ, ºÎ¹®º° ºÐ¼®, Áö¿ª ºÐ¼®, ±â¾÷ °³¿ä µîÀÇ Á¤º¸¸¦ Á¦°øÇϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­·Ð

  • º¸°í¼­ ¼³¸í
    • Á¶»ç ¸ñÀû
    • ½ÃÀå ¹üÀ§
    • °¡Á¤
  • ÀÌÇØ°ü°èÀÚ

Á¦2Àå ÁÖ¿ä ¿ä¾à

  • ½ÃÀå ÇÏÀ̶óÀÌÆ®

Á¦3Àå Á¶»ç ¹æ¹ý

  • °³¿ä
    • µ¥ÀÌÅÍ ¸¶ÀÌ´×
  • Á¤º¸ Ãâó
    • 1Â÷ Á¤º¸
    • 2Â÷ Á¤º¸

Á¦4Àå ¼¼°èÀÇ ¿°Áõ¼º ÀåÁúȯ Ä¡·á ½ÃÀå ÀλçÀÌÆ®

  • ¿°Áõ¼º ÀåÁúȯ Ä¡·á - ¾÷°è ÇöȲ
  • ¿°Áõ¼º ÀåÁúȯ Ä¡·á ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀΰú ±âȸ
    • ¼ºÀå ¾ïÁ¦¿äÀΰú °úÁ¦
  • Porter's Five Forces ºÐ¼®
    • °ø±Þ ±â¾÷ÀÇ Çù»ó·Â
    • ½Å±Ô Âü¿©¾÷üÀÇ À§Çù
    • ±¸¸ÅÀÚÀÇ Çù»ó·Â
    • ´ëüǰÀÇ À§Çù
    • ±âÁ¸ ±â¾÷°£ °æÀï·Â
  • PESTLE ºÐ¼®
  • ¿°Áõ¼º ÀåÁúȯ Ä¡·á ¾÷°è µ¿Çâ
  • ¹ë·ùüÀÎ ºÐ¼®
  • COVID-19 ¿µÇ⠺м®

Á¦5Àå ¼¼°èÀÇ ¿°Áõ¼º ÀåÁúȯ Ä¡·á ½ÃÀå : ÀûÀÀÁõº°

  • ÁÖ¿ä Á¶»ç °á°ú
  • ¼­·Ð
    • ¼¼°èÀÇ ¿°Áõ¼º ÀåÁúȯ Ä¡·á ½ÃÀå : ÀûÀÀÁõº°(2018-2030³â)
  • Å©·Ðº´
    • ¼¼°èÀÇ ¿°Áõ¼º ÀåÁúȯ Ä¡·á ½ÃÀå : Å©·Ðº´º°, Áö¿ªº°(2018-2030³â)
  • ±Ë¾ç¼º ´ëÀå¿°
    • ¼¼°èÀÇ ¿°Áõ¼º ÀåÁúȯ Ä¡·á ½ÃÀå : ±Ë¾ç¼º ´ëÀå¿°º°, Áö¿ªº°(2018-2030³â)

Á¦6Àå ¼¼°èÀÇ ¿°Áõ¼º ÀåÁúȯ Ä¡·á ½ÃÀå : ¾àÁ¦ Ŭ·¡½ºº°

  • ÁÖ¿ä Á¶»ç °á°ú
  • ¼­·Ð
    • ¼¼°èÀÇ ¿°Áõ¼º ÀåÁúȯ Ä¡·á ½ÃÀå : ¾àÁ¦ Ŭ·¡½ºº°(2018-2030³â)
  • ¾Æ¹Ì³ë»ì¸®½Ç»ê¿°
    • ¼¼°èÀÇ ¿°Áõ¼º ÀåÁúȯ Ä¡·á ½ÃÀå : ¾Æ¹Ì³ë»ì¸®½Ç»ê¿°º°, Áö¿ªº°(2018-2030³â)
  • ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀ̵å
    • ¼¼°èÀÇ ¿°Áõ¼º ÀåÁúȯ Ä¡·á ½ÃÀå : ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀ̵庰, Áö¿ªº°(2018-2030³â)
  • TNF ¾ïÁ¦Á¦
    • ¼¼°èÀÇ ¿°Áõ¼º ÀåÁúȯ Ä¡·á ½ÃÀå : TNF ¾ïÁ¦Á¦º°, Áö¿ªº°(2018-2030³â)
  • IL ¾ïÁ¦Á¦
    • ¼¼°èÀÇ ¿°Áõ¼º ÀåÁúȯ Ä¡·á ½ÃÀå : IL ¾ïÁ¦Á¦º°, Áö¿ªº°(2018-2030³â)
  • Ç×ÀÎÅױ׸°Á¦
    • ¼¼°èÀÇ ¿°Áõ¼º ÀåÁúȯ Ä¡·á ½ÃÀå : Ç×ÀÎÅױ׸°Á¦º°, Áö¿ªº°(2018-2030³â)
  • JAK ¾ïÁ¦Á¦
    • ¼¼°èÀÇ ¿°Áõ¼º ÀåÁúȯ Ä¡·á ½ÃÀå : JAK ¾ïÁ¦Á¦º°, Áö¿ªº°(2018-2030³â)
  • ±âŸ
    • ¼¼°èÀÇ ¿°Áõ¼º ÀåÁúȯ Ä¡·á ½ÃÀå : ±âŸº°, Áö¿ªº°(2018-2030³â)

Á¦7Àå ¼¼°èÀÇ ¿°Áõ¼º ÀåÁúȯ Ä¡·á ½ÃÀå : Åõ¿© °æ·Îº°

  • ÁÖ¿ä Á¶»ç °á°ú
  • ¼­·Ð
    • ¼¼°èÀÇ ¿°Áõ¼º ÀåÁúȯ Ä¡·á ½ÃÀå : Åõ¿© °æ·Îº°(2018-2030³â)
  • °æ±¸
    • ¼¼°èÀÇ ¿°Áõ¼º ÀåÁúȯ Ä¡·á ½ÃÀå : °æ±¸º°, Áö¿ªº°(2018-2030³â)
  • ÁÖ»çÁ¦
    • ¼¼°èÀÇ ¿°Áõ¼º ÀåÁúȯ Ä¡·á ½ÃÀå : ÁÖ»çÁ¦º°, Áö¿ªº°(2018-2030³â)

Á¦8Àå ¼¼°èÀÇ ¿°Áõ¼º ÀåÁúȯ Ä¡·á ½ÃÀå : À¯Åë ä³Îº°

  • ÁÖ¿ä Á¶»ç °á°ú
  • ¼­·Ð
    • ¼¼°èÀÇ ¿°Áõ¼º ÀåÁúȯ Ä¡·á ½ÃÀå : À¯Åë ä³Îº°(2018-2030³â)
  • º´¿ø ¾à±¹
    • ¼¼°èÀÇ ¿°Áõ¼º ÀåÁúȯ Ä¡·á ½ÃÀå : º´¿ø ¾à±¹º°, Áö¿ªº°(2018-2030³â)
  • ¼Ò¸Å ¾à±¹
    • ¼¼°èÀÇ ¿°Áõ¼º ÀåÁúȯ Ä¡·á ½ÃÀå : ¼Ò¸Å ¾à±¹º°, Áö¿ªº°(2018-2030³â)
  • ¿Â¶óÀÎ ¾à±¹
    • ¼¼°èÀÇ ¿°Áõ¼º ÀåÁúȯ Ä¡·á ½ÃÀå : ¿Â¶óÀÎ ¾à±¹º°, Áö¿ªº°(2018-2030³â)

Á¦9Àå ¼¼°èÀÇ ¿°Áõ¼º ÀåÁúȯ Ä¡·á ½ÃÀå : Áö¿ªº°

  • ÁÖ¿ä Á¶»ç °á°ú
  • ¼­·Ð
    • ¿°Áõ¼º ÀåÁúȯ Ä¡·á ½ÃÀå Æò°¡ : Áö¿ªº°(2018-2030³â)
  • ºÏ¹Ì
    • ÀûÀÀÁõº°(2018-2030³â)
    • À¯Åë ä³Îº°(2018-2030³â)
    • ¾àÁ¦ Ŭ·¡½ºº°(2018-2030³â)
    • Åõ¿© °æ·Îº°(2018-2030³â)
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´
    • ÀûÀÀÁõº°(2018-2030³â)
    • À¯Åë ä³Îº°(2018-2030³â)
    • ¾àÁ¦ Ŭ·¡½ºº°(2018-2030³â)
    • Åõ¿© °æ·Îº°(2018-2030³â)
    • ¿µ±¹
    • ÇÁ¶û½º
    • µ¶ÀÏ
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • ³×´ú¶õµå
    • ·¯½Ã¾Æ
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ÀûÀÀÁõº°(2018-2030³â)
    • À¯Åë ä³Îº°(2018-2030³â)
    • ¾àÁ¦ Ŭ·¡½ºº°(2018-2030³â)
    • Åõ¿© °æ·Îº°(2018-2030³â)
    • Áß±¹
    • Àεµ
    • ÀϺ»
    • ¸»·¹À̽þÆ
    • Àεµ³×½Ã¾Æ
    • Çѱ¹
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ÀûÀÀÁõº°(2018-2030³â)
    • À¯Åë ä³Îº°(2018-2030³â)
    • ¾àÁ¦ Ŭ·¡½ºº°(2018-2030³â)
    • Åõ¿© °æ·Îº°(2018-2030³â)
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • À̽º¶ó¿¤
    • ¾Æ¶ø¿¡¹Ì¸®Æ®
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ÀûÀÀÁõº°(2018-2030³â)
    • À¯Åë ä³Îº°(2018-2030³â)
    • ¾àÁ¦ Ŭ·¡½ºº°(2018-2030³â)
    • Åõ¿© °æ·Îº°(2018-2030³â)
    • ¸ß½ÃÄÚ
    • ºê¶óÁú
    • ¾Æ¸£ÇîÆ¼³ª

Á¦10Àå °æÀï »óȲ

  • »ç¾÷ È®´ë¿Í Àμö ºÐ¼®
    • »ç¾÷ È®´ë
    • Àμö
  • ÆÄÆ®³Ê½Ê/Çù¾÷/ÇùÁ¤/Àü½Ãȸ

Á¦11Àå ±â¾÷ °³¿ä

  • AbbVie Inc.,
  • Biogen
  • Johnson & Johnson Services, Inc.
  • Amgen Inc.
  • UCB S.A.
  • Novartis AG
  • Takeda Pharmaceutical Company Limited
  • Bausch health companies inc.
  • Bristol-myers squibb company
  • Merck & co., inc.
  • Pfizer Inc.
  • Celltrion Inc.
  • Janssen Biotech
  • Allergan plc.
KSM 22.11.25

The global inflammatory bowel disease treatment market size is expected to reach USD 30.80 billion by 2030, according to a new study by Polaris Market Research. The report "Inflammatory Bowel Disease Treatment Market Share, Size, Trends, Industry Analysis Report, By Disease indication; By Drug Class; By Route of Administration; By Distribution Channel; By Region; Segment Forecast, 2022 - 2030" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The industry for enhanced diagnostic and therapy for inflammatory bowel disease is growing as a result of rising cases of IBD in various regions. The frequency of ulcerative colitis and Crohn's disease is on the rise as a result of a number of variables, such as genetic predisposition, environmental triggers, and immune system disruption.

Most people with Crohn's disease or ulcerative colitis have a family history of the disorder. Each year, 70,000 new cases of IBD are identified, and up to 80,000 youngsters may develop ulcerative colitis or Crohn's disease (CD) (UC). According to Hammer et al., IBD is thought to affect 2.5 to 3 million people in Europe or around 0.3% of the overall population. As per British medical journals, IBD could affect up to 240 000 people in the UK.

Increased disease detection rates and adequate reimbursement regulations in industrialized countries aid industry expansion as early disease diagnosis becomes increasingly crucial. As a result, more patients are obtaining treatment for IBD, which has increased demand for drugs, including toll-like receptor agonists, TNF inhibitors, IL inhibitors, JAK inhibitors, and others that are used to treat the condition.

A larger disease burden of IBD, significant improvements in our understanding of disease pathophysiology, and the development of improved diagnostic and therapeutic drugs are among additional variables that contribute to increased diagnosis rates. In addition to the previously mentioned improvements in access to healthcare systems, better diagnostic techniques for detecting UC early in the illness course, and more knowledge among physicians, patients, and healthcare professionals.

Inflammatory Bowel Disease Treatment Market Report Highlights

In 2021, Crohn's disease dominated the IBD market. It is expected that the segment will remain dominant during the forecast period.

The injectable category dominated the market for the treatment of inflammatory bowel disease in 2021 with a revenue share. The segment's dominance is due to the great efficacy of injectable drugs.

The hospital pharmacy industry dominated the market for the treatment of inflammatory bowel disease in 2021, accounting for the largest revenue share. The sector is predicted to dominate the market during the forecasted period.

The industry players with global presence includes AbbVie, Biogen, Johnson & Johnson, Amgen, UCB S.A., Novartis AG, Takeda Pharmaceutical Company Limited, Bausch Health, Bristol-Myers Squibb Company, Gilead sciences, Merck, Pfizer, Lilly, and Celltrion.

Polaris Market Research has segmented the Inflammatory Bowel Disease Treatment market report based on drug class, route of administration, distribution channel, and region:

Inflammatory Bowel Disease Treatment, Type Outlook (Revenue, USD Million, 2018 - 2030)

Crohn's Disease

Ulcerative Colitis

Inflammatory Bowel Disease Treatment, Drug Class Outlook (Revenue, USD Million, 2018 - 2030)

Amino salicylates

Corticosteroids

TNF inhibitors

IL inhibitors

Anti-integrin

JAK inhibitors

Others

Inflammatory Bowel Disease Treatment, Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)

Oral

Injectable

Inflammatory Bowel Disease Treatment, Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)

Hospital Pharmacy

Retail Pharmacy

Online Pharmacy

Inflammatory Bowel Disease Treatment, Regional Outlook (Revenue, USD Million, 2018 - 2030)

North America

U.S

Canada

Europe

Germany

UK

France

Italy

Spain

Russia

Netherlands

Asia Pacific

China

India

Japan

South Korea

Indonesia

Malaysia

Latin America

Argentina

Brazil

Mexico

Middle East & Africa

UAE

Saudi Arabia

Israel

South Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Inflammatory Bowel Disease Treatment Market Insights

  • 4.1. Inflammatory Bowel Disease Treatment - Industry Snapshot
  • 4.2. Inflammatory Bowel Disease Treatment Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Rising prevalence of Crohn's disease and ulcerative colitis
      • 4.2.1.2. Increasing geriatric population
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. Lack of early diagnosis
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTLE Analysis
  • 4.5. Inflammatory Bowel Disease Treatment Industry Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Inflammatory Bowel Disease Treatment Market, by Disease indication

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Inflammatory Bowel Disease Treatment Market, by Disease indication, 2018 - 2030 (USD Billion)
  • 5.3. Crohn's Disease
    • 5.3.1. Global Inflammatory Bowel Disease Treatment Market, by Crohn's Disease, by Region, 2018 - 2030 (USD Billion)
  • 5.4. Ulcerative Colitis
    • 5.4.1. Global Inflammatory Bowel Disease Treatment Market, by Ulcerative Colitis, by Region, 2018 - 2030 (USD Billion)

6. Global Inflammatory Bowel Disease Treatment Market, by Drug Class Insights

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Inflammatory Bowel Disease Treatment Market, by Drug Class Insights, 2018 - 2030 (USD Billion)
  • 6.3. Amino salicylates
    • 6.3.1. Global Inflammatory Bowel Disease Treatment Market, by Amino salicylates, by Region, 2018 - 2030 (USD Billion)
  • 6.4. Corticosteroids
    • 6.4.1. Global Inflammatory Bowel Disease Treatment Market, by Corticosteroids, by Region, 2018 - 2030 (USD Billion)
  • 6.5. TNF inhibitors
    • 6.5.1. Global Inflammatory Bowel Disease Treatment Market, by TNF inhibitors, by Region, 2018 - 2030 (USD Billion)
  • 6.6. IL inhibitors
    • 6.6.1. Global Inflammatory Bowel Disease Treatment Market, by IL inhibitors, by Region, 2018 - 2030 (USD Billion)
  • 6.7. Anti-integrin
    • 6.7.1. Global Inflammatory Bowel Disease Treatment Market, by Anti-integrin, by Region, 2018 - 2030 (USD Billion)
  • 6.8. JAK inhibitors
    • 6.8.1. Global Inflammatory Bowel Disease Treatment Market, by JAK inhibitors, by Region, 2018 - 2030 (USD Billion)
  • 6.9. Others
    • 6.9.1. Global Inflammatory Bowel Disease Treatment Market, by Others, by Region, 2018 - 2030 (USD Billion)

7. Global Inflammatory Bowel Disease Treatment Market, by Route of Administration

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Inflammatory Bowel Disease Treatment Market, by Route of Administration, 2018 - 2030 (USD Billion)
  • 7.3. Oral
    • 7.3.1. Global Inflammatory Bowel Disease Treatment Market, by Oral, by Region, 2018 - 2030 (USD Billion)
  • 7.4. Injectable
    • 7.4.1. Global Inflammatory Bowel Disease Treatment Market, by Injectable, by Region, 2018 - 2030 (USD Billion)

8. Global Inflammatory Bowel Disease Treatment Market, by Distribution Channel

  • 8.1. Key Findings
  • 8.2. Introduction
    • 8.2.1. Global Inflammatory Bowel Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • 8.3. Hospital Pharmacy
    • 8.3.1. Global Inflammatory Bowel Disease Treatment Market, by Hospital Pharmacy, by Region, 2018 - 2030 (USD Billion)
  • 8.4. Retail Pharmacy
    • 8.4.1. Global Inflammatory Bowel Disease Treatment Market, by Retail Pharmacy, by Region, 2018 - 2030 (USD Billion)
  • 8.5. Online Pharmacy
    • 8.5.1. Global Inflammatory Bowel Disease Treatment Market, by Online Pharmacy, by Region, 2018 - 2030 (USD Billion)

9. Global Inflammatory Bowel Disease Treatment Market, by Geography

  • 9.1. Key findings
  • 9.2. Introduction
    • 9.2.1. Inflammatory Bowel Disease Treatment Market Assessment, By Geography, 2018 - 2030 (USD Billion)
  • 9.3. Inflammatory Bowel Disease Treatment Market - North America
    • 9.3.1. North America: Inflammatory Bowel Disease Treatment Market, by Disease indication, 2018 - 2030 (USD Billion)
    • 9.3.2. North America: Inflammatory Bowel Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Billion)
    • 9.3.3. North America: Inflammatory Bowel Disease Treatment Market, by Drug Class Insights, 2018 - 2030 (USD Billion)
    • 9.3.4. North America: Inflammatory Bowel Disease Treatment Market, by Route of Administration, 2018 - 2030 (USD Billion)
    • 9.3.5. Inflammatory Bowel Disease Treatment Market - U.S.
      • 9.3.5.1. U.S.: Inflammatory Bowel Disease Treatment Market, by Disease indication, 2018 - 2030 (USD Billion)
      • 9.3.5.2. U.S.: Inflammatory Bowel Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Billion)
      • 9.3.5.3. U.S.: Inflammatory Bowel Disease Treatment Market, by Drug Class Insights, 2018 - 2030 (USD Billion)
      • 9.3.5.4. U.S.: Inflammatory Bowel Disease Treatment Market, by Route of Administration, 2018 - 2030 (USD Billion)
    • 9.3.6. Inflammatory Bowel Disease Treatment Market - Canada
      • 9.3.6.1. Canada: Inflammatory Bowel Disease Treatment Market, by Disease indication, 2018 - 2030 (USD Billion)
      • 9.3.6.2. Canada: Inflammatory Bowel Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Billion)
      • 9.3.6.3. Canada: Inflammatory Bowel Disease Treatment Market, by Drug Class Insights, 2018 - 2030 (USD Billion)
      • 9.3.6.4. Canada: Inflammatory Bowel Disease Treatment Market, by Route of Administration, 2018 - 2030 (USD Billion)
  • 9.4. Inflammatory Bowel Disease Treatment Market - Europe
    • 9.4.1. Europe: Inflammatory Bowel Disease Treatment Market, by Disease indication, 2018 - 2030 (USD Billion)
    • 9.4.2. Europe: Inflammatory Bowel Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Billion)
    • 9.4.3. Europe: Inflammatory Bowel Disease Treatment Market, by Drug Class Insights, 2018 - 2030 (USD Billion)
    • 9.4.4. Europe: Inflammatory Bowel Disease Treatment Market, by Route of Administration, 2018 - 2030 (USD Billion)
    • 9.4.5. Inflammatory Bowel Disease Treatment Market - UK
      • 9.4.5.1. UK: Inflammatory Bowel Disease Treatment Market, by Disease indication, 2018 - 2030 (USD Billion)
      • 9.4.5.2. UK: Inflammatory Bowel Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Billion)
      • 9.4.5.3. UK: Inflammatory Bowel Disease Treatment Market, by Drug Class Insights, 2018 - 2030 (USD Billion)
      • 9.4.5.4. UK: Inflammatory Bowel Disease Treatment Market, by Route of Administration, 2018 - 2030 (USD Billion)
    • 9.4.6. Inflammatory Bowel Disease Treatment Market - France
      • 9.4.6.1. France: Inflammatory Bowel Disease Treatment Market, by Disease indication, 2018 - 2030 (USD Billion)
      • 9.4.6.2. France: Inflammatory Bowel Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Billion)
      • 9.4.6.3. France: Inflammatory Bowel Disease Treatment Market, by Drug Class Insights, 2018 - 2030 (USD Billion)
      • 9.4.6.4. France: Inflammatory Bowel Disease Treatment Market, by Route of Administration, 2018 - 2030 (USD Billion)
    • 9.4.7. Inflammatory Bowel Disease Treatment Market - Germany
      • 9.4.7.1. Germany: Inflammatory Bowel Disease Treatment Market, by Disease indication, 2018 - 2030 (USD Billion)
      • 9.4.7.2. Germany: Inflammatory Bowel Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Billion)
      • 9.4.7.3. Germany: Inflammatory Bowel Disease Treatment Market, by Drug Class Insights, 2018 - 2030 (USD Billion)
      • 9.4.7.4. Germany: Inflammatory Bowel Disease Treatment Market, by Route of Administration, 2018 - 2030 (USD Billion)
    • 9.4.8. Inflammatory Bowel Disease Treatment Market - Italy
      • 9.4.8.1. Italy: Inflammatory Bowel Disease Treatment Market, by Disease indication, 2018 - 2030 (USD Billion)
      • 9.4.8.2. Italy: Inflammatory Bowel Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Billion)
      • 9.4.8.3. Italy: Inflammatory Bowel Disease Treatment Market, by Drug Class Insights, 2018 - 2030 (USD Billion)
      • 9.4.8.4. Italy: Inflammatory Bowel Disease Treatment Market, by Route of Administration, 2018 - 2030 (USD Billion)
    • 9.4.9. Inflammatory Bowel Disease Treatment Market - Spain
      • 9.4.9.1. Spain: Inflammatory Bowel Disease Treatment Market, by Disease indication, 2018 - 2030 (USD Billion)
      • 9.4.9.2. Spain: Inflammatory Bowel Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Billion)
      • 9.4.9.3. Spain: Inflammatory Bowel Disease Treatment Market, by Drug Class Insights, 2018 - 2030 (USD Billion)
      • 9.4.9.4. Spain: Inflammatory Bowel Disease Treatment Market, by Route of Administration, 2018 - 2030 (USD Billion)
    • 9.4.10. Inflammatory Bowel Disease Treatment Market - Netherlands
      • 9.4.10.1. Netherlands: Inflammatory Bowel Disease Treatment Market, by Disease indication, 2018 - 2030 (USD Billion)
      • 9.4.10.2. Netherlands: Inflammatory Bowel Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Billion)
      • 9.4.10.3. Netherlands: Inflammatory Bowel Disease Treatment Market, by Drug Class Insights, 2018 - 2030 (USD Billion)
      • 9.4.10.4. Netherlands: Inflammatory Bowel Disease Treatment Market, by Route of Administration, 2018 - 2030 (USD Billion)
    • 9.4.11. Inflammatory Bowel Disease Treatment Market - Russia
      • 9.4.11.1. Russia: Inflammatory Bowel Disease Treatment Market, by Disease indication, 2018 - 2030 (USD Billion)
      • 9.4.11.2. Russia.: Inflammatory Bowel Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Billion)
      • 9.4.11.3. Russia: Inflammatory Bowel Disease Treatment Market, by Drug Class Insights, 2018 - 2030 (USD Billion)
      • 9.4.11.4. Russia: Inflammatory Bowel Disease Treatment Market, by Route of Administration, 2018 - 2030 (USD Billion)
  • 9.5. Inflammatory Bowel Disease Treatment Market - Asia Pacific
    • 9.5.1. Asia Pacific: Inflammatory Bowel Disease Treatment Market, by Disease indication, 2018 - 2030 (USD Billion)
    • 9.5.2. Asia Pacific: Inflammatory Bowel Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Billion)
    • 9.5.3. Asia Pacific: Inflammatory Bowel Disease Treatment Market, by Drug Class Insights, 2018 - 2030 (USD Billion)
    • 9.5.4. Asia Pacific: Inflammatory Bowel Disease Treatment Market, by Route of Administration, 2018 - 2030 (USD Billion)
    • 9.5.5. Inflammatory Bowel Disease Treatment Market - China
      • 9.5.5.1. China: Inflammatory Bowel Disease Treatment Market, by Disease indication, 2018 - 2030 (USD Billion)
      • 9.5.5.2. China.: Inflammatory Bowel Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Billion)
      • 9.5.5.3. China: Inflammatory Bowel Disease Treatment Market, by Drug Class Insights, 2018 - 2030 (USD Billion)
      • 9.5.5.4. China: Inflammatory Bowel Disease Treatment Market, by Route of Administration, 2018 - 2030 (USD Billion)
    • 9.5.6. Inflammatory Bowel Disease Treatment Market - India
      • 9.5.6.1. India: Inflammatory Bowel Disease Treatment Market, by Disease indication, 2018 - 2030 (USD Billion)
      • 9.5.6.2. India.: Inflammatory Bowel Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Billion)
      • 9.5.6.3. India: Inflammatory Bowel Disease Treatment Market, by Drug Class Insights, 2018 - 2030 (USD Billion)
      • 9.5.6.4. India: Inflammatory Bowel Disease Treatment Market, by Route of Administration, 2018 - 2030 (USD Billion)
    • 9.5.7. Inflammatory Bowel Disease Treatment Market - Japan
      • 9.5.7.1. Japan: Inflammatory Bowel Disease Treatment Market, by Disease indication, 2018 - 2030 (USD Billion)
      • 9.5.7.2. Japan.: Inflammatory Bowel Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Billion)
      • 9.5.7.3. Japan: Inflammatory Bowel Disease Treatment Market, by Drug Class Insights, 2018 - 2030 (USD Billion)
      • 9.5.7.4. Japan: Inflammatory Bowel Disease Treatment Market, by Route of Administration, 2018 - 2030 (USD Billion)
    • 9.5.8. Inflammatory Bowel Disease Treatment Market - Malaysia
      • 9.5.8.1. Malaysia: Inflammatory Bowel Disease Treatment Market, by Disease indication, 2018 - 2030 (USD Billion)
      • 9.5.8.2. Malaysia.: Inflammatory Bowel Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Billion)
      • 9.5.8.3. Malaysia: Inflammatory Bowel Disease Treatment Market, by Drug Class Insights, 2018 - 2030 (USD Billion)
      • 9.5.8.4. Malaysia: Inflammatory Bowel Disease Treatment Market, by Route of Administration, 2018 - 2030 (USD Billion)
    • 9.5.9. Inflammatory Bowel Disease Treatment Market - Indonesia
      • 9.5.9.1. Indonesia: Inflammatory Bowel Disease Treatment Market, by Disease indication, 2018 - 2030 (USD Billion)
      • 9.5.9.2. Indonesia.: Inflammatory Bowel Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Billion)
      • 9.5.9.3. Indonesia: Inflammatory Bowel Disease Treatment Market, by Drug Class Insights, 2018 - 2030 (USD Billion)
      • 9.5.9.4. Indonesia: Inflammatory Bowel Disease Treatment Market, by Route of Administration, 2018 - 2030 (USD Billion)
    • 9.5.10. Inflammatory Bowel Disease Treatment Market - South Korea
      • 9.5.10.1. South Korea: Inflammatory Bowel Disease Treatment Market, by Disease indication, 2018 - 2030 (USD Billion)
      • 9.5.10.2. South Korea.: Inflammatory Bowel Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Billion)
      • 9.5.10.3. South Korea: Inflammatory Bowel Disease Treatment Market, by Drug Class Insights, 2018 - 2030 (USD Billion)
      • 9.5.10.4. South Korea: Inflammatory Bowel Disease Treatment Market, by Route of Administration, 2018 - 2030 (USD Billion)
  • 9.6. Inflammatory Bowel Disease Treatment Market - Middle East & Africa
    • 9.6.1. Middle East & Africa: Inflammatory Bowel Disease Treatment Market, by Disease indication, 2018 - 2030 (USD Billion)
    • 9.6.2. Middle East & Africa: Inflammatory Bowel Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Billion)
    • 9.6.3. Middle East & Africa: Inflammatory Bowel Disease Treatment Market, by Drug Class Insights, 2018 - 2030 (USD Billion)
    • 9.6.4. Middle East & Africa: Inflammatory Bowel Disease Treatment Market, by Route of Administration, 2018 - 2030 (USD Billion)
    • 9.6.5. Inflammatory Bowel Disease Treatment Market - Saudi Arabia
      • 9.6.5.1. Saudi Arabia: Inflammatory Bowel Disease Treatment Market, by Disease indication, 2018 - 2030 (USD Billion)
      • 9.6.5.2. Saudi Arabia: Inflammatory Bowel Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Billion)
      • 9.6.5.3. Saudi Arabia: Inflammatory Bowel Disease Treatment Market, by Drug Class Insights, 2018 - 2030 (USD Billion)
      • 9.6.5.4. Saudi Arabia: Inflammatory Bowel Disease Treatment Market, by Route of Administration, 2018 - 2030 (USD Billion)
    • 9.6.6. Inflammatory Bowel Disease Treatment Market - South Africa
      • 9.6.6.1. South Africa: Inflammatory Bowel Disease Treatment Market, by Disease indication, 2018 - 2030 (USD Billion)
      • 9.6.6.2. South Africa: Inflammatory Bowel Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Billion)
      • 9.6.6.3. South Africa: Inflammatory Bowel Disease Treatment Market, by Drug Class Insights, 2018 - 2030 (USD Billion)
      • 9.6.6.4. South Africa: Inflammatory Bowel Disease Treatment Market, by Route of Administration, 2018 - 2030 (USD Billion)
    • 9.6.7. Inflammatory Bowel Disease Treatment Market - Israel
      • 9.6.7.1. Israel: Inflammatory Bowel Disease Treatment Market, by Disease indication, 2018 - 2030 (USD Billion)
      • 9.6.7.2. Israel: Inflammatory Bowel Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Billion)
      • 9.6.7.3. Israel: Inflammatory Bowel Disease Treatment Market, by Drug Class Insights, 2018 - 2030 (USD Billion)
      • 9.6.7.4. Israel: Inflammatory Bowel Disease Treatment Market, by Route of Administration, 2018 - 2030 (USD Billion)
    • 9.6.8. Inflammatory Bowel Disease Treatment Market - UAE
      • 9.6.8.1. UAE: Inflammatory Bowel Disease Treatment Market, by Disease indication, 2018 - 2030 (USD Billion)
      • 9.6.8.2. UAE: Inflammatory Bowel Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Billion)
      • 9.6.8.3. UAE: Inflammatory Bowel Disease Treatment Market, by Drug Class Insights, 2018 - 2030 (USD Billion)
      • 9.6.8.4. UAE: Inflammatory Bowel Disease Treatment Market, by Route of Administration, 2018 - 2030 (USD Billion)
  • 9.7. Inflammatory Bowel Disease Treatment Market - Latin America
    • 9.7.1. Latin America: Inflammatory Bowel Disease Treatment Market, by Disease indication, 2018 - 2030 (USD Billion)
    • 9.7.2. Latin America: Inflammatory Bowel Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Billion)
    • 9.7.3. Latin America: Inflammatory Bowel Disease Treatment Market, by Drug Class Insights, 2018 - 2030 (USD Billion)
    • 9.7.4. Latin America: Inflammatory Bowel Disease Treatment Market, by Route of Administration, 2018 - 2030 (USD Billion)
    • 9.7.5. Inflammatory Bowel Disease Treatment Market - Mexico
      • 9.7.5.1. Mexico: Inflammatory Bowel Disease Treatment Market, by Disease indication, 2018 - 2030 (USD Billion)
      • 9.7.5.2. Mexico: Inflammatory Bowel Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Billion)
      • 9.7.5.3. Mexico: Inflammatory Bowel Disease Treatment Market, by Drug Class Insights, 2018 - 2030 (USD Billion)
      • 9.7.5.4. Mexico: Inflammatory Bowel Disease Treatment Market, by Route of Administration, 2018 - 2030 (USD Billion)
    • 9.7.6. Inflammatory Bowel Disease Treatment Market - Brazil
      • 9.7.6.1. Brazil: Inflammatory Bowel Disease Treatment Market, by Disease indication, 2018 - 2030 (USD Billion)
      • 9.7.6.2. Brazil: Inflammatory Bowel Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Billion)
      • 9.7.6.3. Brazil: Inflammatory Bowel Disease Treatment Market, by Drug Class Insights, 2018 - 2030 (USD Billion)
      • 9.7.6.4. Brazil: Inflammatory Bowel Disease Treatment Market, by Route of Administration, 2018 - 2030 (USD Billion)
    • 9.7.7. Inflammatory Bowel Disease Treatment Market - Argentina
      • 9.7.7.1. Argentina: Inflammatory Bowel Disease Treatment Market, by Disease indication, 2018 - 2030 (USD Billion)
      • 9.7.7.2. Argentina: Inflammatory Bowel Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Billion)
      • 9.7.7.3. Argentina: Inflammatory Bowel Disease Treatment Market, by Drug Class Insights, 2018 - 2030 (USD Billion)
      • 9.7.7.4. Argentina: Inflammatory Bowel Disease Treatment Market, by Route of Administration, 2018 - 2030 (USD Billion)

10. Competitive Landscape

  • 10.1. Expansion and Acquisition Analysis
    • 10.1.1. Expansion
    • 10.1.2. Acquisitions
  • 10.2. Partnerships/Collaborations/Agreements/Exhibitions

11. Company Profiles

  • 11.1. AbbVie Inc.,
    • 11.1.1. Company Overview
    • 11.1.2. Financial Performance
    • 11.1.3. Disease indication Benchmarking
    • 11.1.4. Recent Development
  • 11.2. Biogen
    • 11.2.1. Company Overview
    • 11.2.2. Financial Performance
    • 11.2.3. Disease indication Benchmarking
    • 11.2.4. Recent Development
  • 11.3. Johnson & Johnson Services, Inc.
    • 11.3.1. Company Overview
    • 11.3.2. Financial Performance
    • 11.3.3. Disease indication Benchmarking
    • 11.3.4. Recent Development
  • 11.4. Amgen Inc.
    • 11.4.1. Company Overview
    • 11.4.2. Financial Performance
    • 11.4.3. Disease indication Benchmarking
    • 11.4.4. Recent Development
  • 11.5. UCB S.A.
    • 11.5.1. Company Overview
    • 11.5.2. Financial Performance
    • 11.5.3. Disease indication Benchmarking
    • 11.5.4. Recent Development
  • 11.6. Novartis AG
    • 11.6.1. Company Overview
    • 11.6.2. Financial Performance
    • 11.6.3. Disease indication Benchmarking
    • 11.6.4. Recent Development
  • 11.7. Takeda Pharmaceutical Company Limited
    • 11.7.1. Company Overview
    • 11.7.2. Financial Performance
    • 11.7.3. Disease indication Benchmarking
    • 11.7.4. Recent Development
  • 11.8. Bausch health companies inc.
    • 11.8.1. Company Overview
    • 11.8.2. Financial Performance
    • 11.8.3. Disease indication Benchmarking
    • 11.8.4. Recent Development
  • 11.9. Bristol-myers squibb company
    • 11.9.1. Company Overview
    • 11.9.2. Financial Performance
    • 11.9.3. Disease indication Benchmarking
    • 11.9.4. Recent Development
  • 11.10. Merck & co., inc.
    • 11.10.1. Company Overview
    • 11.10.2. Financial Performance
    • 11.10.3. Disease indication Benchmarking
    • 11.10.4. Recent Development
  • 11.11. Pfizer Inc.
    • 11.11.1. Company Overview
    • 11.11.2. Financial Performance
    • 11.11.3. Disease indication Benchmarking
    • 11.11.4. Recent Development
  • 11.12. Celltrion Inc.
    • 11.12.1. Company Overview
    • 11.12.2. Financial Performance
    • 11.12.3. Disease indication Benchmarking
    • 11.12.4. Recent Development
  • 11.13. Janssen Biotech
    • 11.13.1. Company Overview
    • 11.13.2. Financial Performance
    • 11.13.3. Disease indication Benchmarking
    • 11.13.4. Recent Development
  • 11.14. Allergan plc.
    • 11.14.1. Company Overview
    • 11.14.2. Financial Performance
    • 11.14.3. Disease indication Benchmarking
    • 11.14.4. Recent Development
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦